News
RGLS
2.480
+4.64%
0.110
Weekly Report: what happened at RGLS last week (0610-0614)?
Weekly Report · 1d ago
Weekly Report: what happened at RGLS last week (0603-0607)?
Weekly Report · 06/10 10:13
Analysts Offer Insights on Healthcare Companies: DarioHealth (DRIO) and Regulus (RGLS)
TipRanks · 06/04 09:00
Weekly Report: what happened at RGLS last week (0527-0531)?
Weekly Report · 06/03 10:15
Regulus Therapeutics Initiated at Buy by Jones Trading
Dow Jones · 05/31 13:08
Regulus Therapeutics Price Target Announced at $8.00/Share by Jones Trading
Dow Jones · 05/31 13:08
Jones Trading Initiates Coverage On Regulus Therapeutics with Buy Rating, Announces Price Target of $8
Benzinga · 05/31 12:58
Weekly Report: what happened at RGLS last week (0520-0524)?
Weekly Report · 05/27 10:17
Weekly Report: what happened at RGLS last week (0513-0517)?
Weekly Report · 05/20 10:13
Regulus Sets Governance and Incentive Path at Annual Meeting
TipRanks · 05/17 20:14
Regulus Therapeutics names Rekha Garg as chief medical officer
Healthcare Regulus Therapeutics names Rekha Garg as chief medical officer. Garg previously served as the company's senior vice president, clinical development and regulatory. Regulus has over 20 years of experience in the industry. Regulus is a subsidiary of Regulus Pharmaceuticals Inc.
Seeking Alpha · 05/16 12:17
REGULUS THERAPEUTICS ANNOUNCES PROMOTION OF REKHA GARG, M.D., M.S., TO CHIEF MEDICAL OFFICER
Reuters · 05/16 12:00
Press Release: Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
Dow Jones · 05/16 12:00
Analysts’ Top Healthcare Picks: Xenon (XENE), Progyny (PGNY)
TipRanks · 05/14 12:30
Weekly Report: what happened at RGLS last week (0506-0510)?
Weekly Report · 05/13 10:18
Analysts Are Bullish on Top Healthcare Stocks: Regulus (RGLS), Zevra Therapeutics (ZVRA)
TipRanks · 05/10 15:20
Regulus Therapeutics Inc. Quarterly Report for the Period Ended March 31, 2024
Press release · 05/10 14:14
Regulus Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.
Dow Jones · 05/10 12:01
HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target
Benzinga · 05/10 11:51
Buy Rating Affirmed for Regulus Therapeutics Amid Positive Clinical Advances for RGLS8429
TipRanks · 05/10 10:46
More
Webull provides a variety of real-time RGLS stock news. You can receive the latest news about Regulus Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About RGLS
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing drugs targeting microRNAs to treat diseases with significant unmet medical need. The Company is focused on orphan kidney diseases where microRNA genetic drivers are implicated and there are clear unmet medical needs. Its product candidate, RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), is in Phase 1b clinical development. In addition to this program, the Company continues to advance and expand its internal discovery pipeline to identify potential product candidates. microRNAs are naturally occurring ribonucleic acid (RNA) molecules that play a critical role in regulating key biological pathways. ADPKD is among the common human monogenic disorders and a cause of end-stage renal disease.